title: Association between urinary 6β-hydroxycortisol/cortisol ratio and CYP3A5 genotypes in a normotensive population.
abstract: Genetic polymorphism of genes involved in renal salt handling and arterial vessel tone is considered to be one of the causes of hypertension. Numerous reports suggest that cytochrome P4503A5 (CYP3A5) catalyzes 6β-hydroxylation of endogenous cortisol (CS), which is associated with sodium and water retention in the kidney and involved in the regulation of blood pressure. The purpose of the present study was to study the associations of single nucleotide polymorphisms in the CYP3A5 gene with the urinary 6β-hydroxycortisol/cortisol (6β-OH-CS/CS) ratio considered as quantitative phenotypes. CS measurements of three hundred (n=300) healthy, normotensive North Indian individuals was performed on morning spot urine samples by high-performance liquid chromatography. Furthermore, genotyping for CYP3A5*3 and CYP3A5*6 was performed by PCR-RFLP. The results indicated a unimodal distribution of CYP3A phenotypes in the North Indian population. In further analysis, all the phenotypes were distributed into three groups, demonstrating low (n=75), intermediate (n=150) and high CYP3A activity (n=75) based on CS and 6β-OH-CS levels and log 6β-OH-CS/CS ratios. The subjects in the low and high activity groups were genotyped for the CYP3A5*3 and *6 alleles. The present study demonstrated that the allele frequencies of CYP3A5*1 and *3 were 0.29 (95% CI, 0.22-0.36) and 0.71 (95% CI, 0.64-0.78), respectively. Notably, the frequency of normal homozygotes (CYP3A5*1/*1) was significantly higher in the high activity than the low activity group (11% vs. 5%). Similarly, the frequency of mutant homozygotes (CYP3A5*3/*3) was significantly higher in the low activity group than the high activity group (57% vs. 44%). The allele frequency of CYP3A5*3 was significantly higher in the low activity group (0.76) than the high activity group (0.67). The mean 6β-OH-CS/CS ratios were 110, 76 and 69 in wild-type homozygotes (n=12), heterozygotes (n=62) and mutant homozygotes (n=76), respectively. The difference between the normal and mutant homozygotes was statistically significant (P<0.05). The CYP3A5*6 allele was absent from all the subjects genotyped. This is the first study to report the genetic polymorphism of CYP3A5 in a North Indian population and its association with urinary 6β-OH-CS/CS ratio reflecting the CYP3A phenotypes.
authors: Department of Biotechnology, Manipal University, Dubai,  United Arab Emirates ;
authors: Naushad
authors: N
authors: Rais
authors: Arif
authors: A
authors: Hussain
authors: Yogesh Kumar
authors: YK
authors: Chawla
authors: Krishan K
authors: KK
authors: Kohli
keywords: North Indians; cytochrome P4503A; genetic polymorphism; hypertension; pharmacogenetics
references: Drug Metab Dispos. 2002 Oct;30(10):1108-14
references: 12228187
references: Hypertens Res. 2011 Nov;34(11):1216-20
references: 21814220
references: Clin Pharmacol Ther. 2007 Mar;81(3):386-91
references: 17339868
references: Pharmacogenomics. 2004 Apr;5(3):243-72
references: 15102541
references: J Clin Endocrinol Metab. 1975 Jun;40(6):949-58
references: 1133161
references: Br J Clin Pharmacol. 2003 Sep;56(3):331-3
references: 12919183
references: Methods Enzymol. 1996;272:199-210
references: 8791778
references: Hypertension. 2007 May;49(5):1007-14
references: 17372036
references: Hypertension. 2005 Feb;45(2):294-8
references: 15596575
references: Eur J Clin Pharmacol. 2006 Jun;62(6):417-22
references: 16758258
references: Arch Intern Med. 1989 Apr;149(4):780-8
references: 2784957
references: Clin Pharmacol Ther. 1992 Jan;51(1):18-23
references: 1732074
references: Biochim Biophys Acta. 1993 Sep 8;1182(2):152-6
references: 8357846
references: Drug Metab Dispos. 2012 Apr;40(4):639-41
references: 22214815
references: Mol Pharmacol. 1996 Jul;50(1):52-9
references: 8700118
references: Hypertension. 1996 Mar;27(3 Pt 2):481-90
references: 8613190
references: J Hum Hypertens. 2010 May;24(5):345-50
references: 19812606
references: Endocrinology. 1985 Mar;116(3):1189-94
references: 3971902
references: J Biol Chem. 1989 Jun 25;264(18):10388-95
references: 2732228
references: Clin Pharmacokinet. 2006;45(1):13-31
references: 16430309
references: J Appl Physiol (1985). 2003 Sep;95(3):1297-300
references: 12754175
references: Nat Genet. 2001 Apr;27(4):383-91
references: 11279519
references: Am J Physiol. 1988 Oct;255(4 Pt 2):F736-48
references: 3177656
references: Clin Pharmacol Ther. 2000 Sep;68(3):328-35
references: 11014415
references: Eur J Clin Pharmacol. 2003 Jun;59(2):123-6
references: 12756511
references: Drug Metab Dispos. 2012 Feb;40(2):389-96
references: 22096084
references: Am J Physiol. 1992 Jun;262(6 Pt 2):F927-31
references: 1621817
references: Clin Chem. 2005 Aug;51(8):1374-81
references: 15951320
references: Drug Metab Dispos. 2004 Dec;32(12):1434-45
references: 15383492